100XBIO is at the forefront of T-cell analysis technology, offering innovative solutions that significantly enhance the research and development of T cell-mediated therapies. Central to their offerings is the 100XBIO Cycler, a robotic platform that simulates the action of a real lymph node, allowing for the re-testing of biological samples. This technology enables researchers to conduct up to 100 cycles of antigen-specific stimulation, resulting in a remarkable amplification of data—up to 100 times more antigen-specific stimulation data from small biosample volumes, such as blood, lymph nodes, and tumors. Additionally, the platform supports live T-cell imaging, which focuses on observing T-cell responses post-activation, thereby providing critical insights into immune responses.

The applications of 100XBIO's technology are diverse and impactful, particularly in the fields of personalized medicine and clinical trials. For instance, their system allows for the validation of up to 40 individual neoantigen targets in less than 24 hours, using significantly reduced blood volumes, which streamlines the process of neoantigen epitope validation. Furthermore, the technology enhances the tracking of vaccine T-cell responses, potentially simplifying patient enrollment in clinical trials and improving data robustness. In the realm of adoptive cell therapy, 100XBIO's innovations lead to better detection and analysis of immune cell activation, ultimately contributing to improved therapeutic outcomes and advancing the development of vaccines and diagnostics.

United States

At 100XBIO we strive to deliver 100x more data on antigen specificity of the T cells in the limited sample volume (blood, tumor, lymph nodes), and as the downstream -- confirming the cells' phenotype and cytokine expression.

Looking for (1) early investments, (2) R&D partners, and (3) early academia, biotech and pharma clients. We are raising $500K of pre-seed investment, and raised over $200K.

100XBIO

Company Details